Back to top
more

HTG Molecular Diagnostics, Inc. (HTGM)

(Delayed Data from NSDQ)

$2.59 USD

2.59
424,944

+0.10 (4.02%)

Updated May 3, 2019 04:00 PM ET

After-Market: $2.58 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

KORU Medical Systems Inc. (KRMD) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

KORU Medical Systems Inc. (KRMD) delivered earnings and revenue surprises of -25% and 1%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

LivaNova (LIVN) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

LivaNova (LIVN) delivered earnings and revenue surprises of 4.88% and 8.59%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

TransMedics (TMDX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

TransMedics (TMDX) delivered earnings and revenue surprises of 68% and 19.72%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Molecular Templates Inc. (MTEM) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Molecular Templates Inc. (MTEM) delivered earnings and revenue surprises of -56% and 63.99%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

HTG Molecular Diagnostics, Inc. (HTGM) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

HTG Molecular Diagnostics, Inc. (HTGM) delivered earnings and revenue surprises of 21.15% and 44.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Neuronetics (STIM) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Neuronetics (STIM) delivered earnings and revenue surprises of 36.36% and 11.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ReWalk Robotics (RWLK) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

ReWalk (RWLK) delivered earnings and revenue surprises of -50% and 51.32%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

HTG Molecular Diagnostics, Inc. (HTGM) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

HTG Molecular Diagnostics, Inc. (HTGM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Treace Medical Concepts (TMCI) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Treace Medical Concepts (TMCI) delivered earnings and revenue surprises of -9.52% and 4.38%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Inogen (INGN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Inogen (INGN) delivered earnings and revenue surprises of 95% and 2.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

HTG Molecular Diagnostics, Inc. (HTGM) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

HTG Molecular Diagnostics, Inc. (HTGM) delivered earnings and revenue surprises of -14.08% and 15.43%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ConforMIS (CFMS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

ConforMIS (CFMS) delivered earnings and revenue surprises of -28.57% and 11.58%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: HTG Molecular Diagnostics, Inc. (HTGM) Q4 Earnings Expected to Decline

by Zacks Equity Research

HTG Molecular Diagnostics, Inc. (HTGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HTG Molecular Diagnostics, Inc. (HTGM) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

HTG Molecular Diagnostics, Inc. (HTGM) delivered earnings and revenue surprises of 0.00% and 3.32%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Will HTG Molecular Diagnostics, Inc. (HTGM) Report Negative Q2 Earnings? What You Should Know

by Zacks Equity Research

HTG Molecular Diagnostics, Inc. (HTGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Top Ranked Momentum Stocks to Buy for May 14th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 14th

HTG Molecular Diagnostics Inc (HTGM) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

HTG Molecular Diagnostics Inc (HTGM) delivered earnings and revenue surprises of 0.00% and -2.41%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

HTG Molecular Diagnostics Inc (HTGM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

HTG Molecular Diagnostics Inc (HTGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: HTG Molecular Diagnostics, Inc. (HTGM) Q4 Earnings Expected to Decline

by Zacks Equity Research

HTG Molecular Diagnostics, Inc. (HTGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: HTG Molecular Diagnostics, Inc. (HTGM) Q4 Earnings Expected to Decline

by Zacks Equity Research

HTG Molecular Diagnostics, Inc. (HTGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HTG Molecular Diagnostics, Inc. (HTGM) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

HTG Molecular Diagnostics, Inc. (HTGM) delivered earnings and revenue surprises of -7.14% and -3.91%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

HTG Molecular Diagnostics, Inc. (HTGM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

HTG Molecular Diagnostics, Inc. (HTGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HTG Molecular Diagnostics, Inc. (HTGM) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

HTG Molecular Diagnostics, Inc. (HTGM) delivered earnings and revenue surprises of -13.33% and 4.62%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate HTG Molecular Diagnostics, Inc. (HTGM) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

HTG Molecular Diagnostics, Inc. (HTGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HTG Molecular Diagnostics, Inc. (HTGM) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

HTG Molecular Diagnostics, Inc. (HTGM) delivered earnings and revenue surprises of -11.76% and 15.84%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?